Neidio i'r prif gynnwy

Gwasanaethau Pediatrig

 Berotralstat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement (PP236). June 2022 (Saesneg) (PDF, 277Kb)
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome or Lennox–Gastaut syndrome in people aged 2 years and older, Policy Position Statement (PP203), July 2024 (Saesneg) (PDF, 309Kb)
 Circumcision for Children, Commissioning Policy, (CP34). December 2024 (Saesneg) (PDF, 344Kb)
 Cleft Lip and/or Palate including Non-Cleft Velopharyngael Dysfuncion: All Ages, Service Specification (CP186), November 2025 (Saesneg) (PDF, 591Kb)
 Corneal cross-linking for keratoconus in children (from birth until their 16th birthday) commissioning policy, (CP271), October 2023 (Saesneg) (PDF, 328Kb)
 Dexrazoxane for Preventing Cardiotoxicity in Children (Aged Under 16 Years Old) Receiving High-Dose Anthracyclines or Related Drugs for the Treatment of Cancer, Policy Position Statement (PP253), February 2023 (PDF, 265Kb)
 Lumasiran for treating primary hyperoxaluria type 1, Policy Position Statement (PP277), December 2026 (Saesneg) (PDF, 250Kb)
 Nusinersen for treating spinal muscular atrophy, Policy Position Statement (PP191), November 2026 (Saesneg) (PDF, 400Kb)
 Paediatric Endocrinology, Service Specification (CP163), July 2024 (Saesneg) (PDF, 283Kb)
 Paediatric Epilepsy, Commissioning Policy (CP174), September 2022 (Saesneg) (PDF, 487Kb)
 Paediatric Nephrology Service Specification CP169 (March 2021) (Saesneg) (PDF, 443Kb)
 Risdiplam for Spinal Muscular Atrophy for people aged under 16 years, Policy Position Statement (PP240). May 2022 (Saesneg) (PDF, 361Kb)
 South Wales Neonatal Transport Operational Delivery Network, (CP244) October 2022 (Saesneg) (PDF, 303Kb)
 Specialised Fetal Medicine, Commissioning Policy, (CP97), October 2023 (Saesneg) (PDF, 372Kb)
 Specialised Paediatric Gastroenterology, Hepatology and Nutrition (PGHAN) (CP211) May 2023 (Saesneg) (PDF, 759Kb)
 Specialised Paediatric Rheumatology Service Specification (CP172). November 2021 (Saesneg) (PDF, 475Kb)
 Tofacitinib for treating juvenile idiopathic arthritis in people aged 2 to 16 years, Policy Position Statement (PP229). May 2022 (Saesneg) (PDF, 311Kb)